Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sandra Bruder
Institution:
Bayer (Germany)
Observed institutions:
University of Washington,
Bayer (Germany),
University of Tübingen
OpenAlex ID:
A5048811845
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
2014
·
Sven Golfier
, Charlotte Kopitz
, et al.
·
Molecular Cancer Therapeutics
·
266
Crystal structure of the tandem GAF domains from a cyanobacterial adenylyl cyclase: Modes of ligand binding and dimerization
2005
·
Sergio E. Martinez
, Sandra Bruder
, et al.
·
Proceedings of the National Academy of Sciences
·
95
The cyanobacterial tandem GAF domains from the cyaB2 adenylyl cyclase signal via both cAMP-binding sites
2005
·
Sandra Bruder
, Jürgen U. Linder
, et al.
·
Proceedings of the National Academy of Sciences
·
47
Characterization of the Tandem GAF Domain of Human Phosphodiesterase 5 Using a Cyanobacterial Adenylyl Cyclase as a Reporter Enzyme
2006
·
Sandra Bruder
, Anita Schultz
, et al.
·
Journal of Biological Chemistry
·
29
Changes in purine specificity in tandem GAF chimeras from cyanobacterial cyaB1 adenylate cyclase and rat phosphodiesterase 2
2007
·
Jürgen U. Linder
, Sandra Bruder
, et al.
·
FEBS Journal
·
11
PDF
Abstract 1754: Identification of BAY 94-9343, a mesothelin antibody-drug conjugate (ADC): Characterization and anti-tumor activity in mesothelin-positive preclinical tumor models
2011
·
Sven Golfier
, Antje Kahnert
, et al.
·
Cancer Research
·
5
cAMP- und cGMP-bindende Tandem-GAF-Domänen: Biochemische Untersuchungen mit einer cyanobakteriellen Adenylatcyclase
2006
·
Sandra Bruder
·
2
Data from Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
2023
·
Sven Golfier
, Charlotte Kopitz
, et al.
Supplementary Figures 1 through 6 from Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
2023
·
Sven Golfier
, Charlotte Kopitz
, et al.
PDF
Supplementary Table 1 from Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
2023
·
Sven Golfier
, Charlotte Kopitz
, et al.
PDF
Supplementary Materials and Methods and Supplementary Figure Legends from Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
2023
·
Sven Golfier
, Charlotte Kopitz
, et al.
Data from Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
2023
·
Sven Golfier
, Charlotte Kopitz
, et al.
Bacterial GAF domains
2005
·
Joachim E Schultz
, Sandra Bruder
, et al.
·
BMC Pharmacology
PDF
Show more works
View as search
Works count:
13
Citation count:
455
H-index:
5
I10-index:
5
Year
Topic
Type